The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep

被引:10
|
作者
Chang, Cheng
Tang, Xin
Woodley, David T.
Chen, Mei
Li, Wei [1 ]
机构
[1] Univ Southern Calif, Keck Med Ctr, Dept Dermatol, Los Angeles, CA 90033 USA
关键词
heat shock protein-90; Hsp90-alpha; Hsp90-beta; distinctions; Hsp90; inhibitors; therapeutics; SHOCK-PROTEIN; 90ALPHA; MOLECULAR CHAPERONE; TYROSINE KINASE; CANCER; INHIBITORS; RECEPTOR; HYPOXIA; GROWTH; EXPRESSION; BIOMARKER;
D O I
10.3390/cells12020277
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
For decades, the undisputable definition of the cytosolic Hsp90 alpha and hsp90 beta proteins being evolutionarily conserved, ATP-driven chaperones has ruled basic research and clinical trials. The results of recent studies, however, have fundamentally challenged this paradigm, not to mention the spectacular failures of the paradigm-based clinical trials in cancer and beyond. We now know that Hsp90 alpha and Hsp90 beta are both ubiquitously expressed in all cell types but assigned for distinct and irreplaceable functions. Hsp90 beta is essential during mouse development and Hsp90 alpha only maintains male reproductivity in adult mice. Neither Hsp90 beta nor Hsp90 alpha could substitute each other under these biological processes. Hsp90 beta alone maintains cell survival in culture and Hsp90 alpha cannot substitute it. Hsp90 alpha also has extracellular functions under stress and Hsp90 beta does not. The dramatic difference in the steady-state expression of Hsp90 in different mouse organs is due to the variable expressions of Hsp90 alpha. The lowest expression of Hsp90 is less than 2% and the highest expression of Hsp90 is 9% among non-transformed cell lines. The two linker regions only take up less than 5% of the Hsp90 proteins, but harbor 21% of the total amino acid substitutions, i.e., 40% in comparison to the 86% overall amino acid homology. A full understanding of the distinctions between Hsp90 alpha and Hsp90 beta could lead to new, safe and effective therapeutics targeting Hsp90 in human disorders such as cancer. This is the first comprehensive review of a comparison between the two cytosolic Hsp90 isoforms.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] HSP90 manages the ends
    DeZwaan, Diane C.
    Freeman, Brian C.
    TRENDS IN BIOCHEMICAL SCIENCES, 2010, 35 (07) : 384 - 391
  • [42] The Hsp90 chaperone machinery
    Wandinger, Sebastian Karl
    Richter, Klaus
    Buchner, Johannes
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (27) : 18473 - 18477
  • [43] Hsp90: Breaking the Symmetry
    Mayer, Matthias P.
    Le Breton, Laura
    MOLECULAR CELL, 2015, 58 (01) : 8 - 20
  • [44] The HSP90 complex of plants
    Kadota, Yasuhiro
    Shirasu, Ken
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2012, 1823 (03): : 689 - 697
  • [45] The role of HSP90 in evolution
    Yahara, I
    GENES TO CELLS, 1999, 4 (07) : 375 - 379
  • [46] Regulation of the Hsp90 system
    Sima, Siyuan
    Richter, Klaus
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2018, 1865 (06): : 889 - 897
  • [47] Hsp90: the vulnerable chaperone
    Chiosis, G
    Vilenchik, M
    Kim, J
    Solit, D
    DRUG DISCOVERY TODAY, 2004, 9 (20) : 881 - 888
  • [48] Hsp90: A Drug Target?
    Jeffrey M. Holzbeierlein
    Andrew Windsperger
    George Vielhauer
    Current Oncology Reports, 2010, 12 : 95 - 101
  • [49] Better HSP90 inhibitors
    Harrison Charlotte
    Nature Reviews Drug Discovery, 2013, 12 (5) : 346 - 346
  • [50] Hsp90 invades the outside
    Didier Picard
    Nature Cell Biology, 2004, 6 : 479 - 480